[Orthocell (ASX:OCC) has released the final results from a clinical study comparing its autologous cell therapy, OrthoATI, to surgery for the treatment of severe, chronic, treatment-resistant lateral epicondylitis, also known as tennis elbow. The study confirmed that OrthoATI is as effective as surgery in treating this condition.
Lateral epicondylitis is a condition that causes significant pain and disability and affects millions of people each year. Conservative treatments such as rest, nonsteroidal anti-inflammatory drugs, and physiotherapy are usually effective, with symptoms resolving within six months. If symptoms persist, patients may be offered steroid injections. However, approximately 10-20% of patients do not respond to these treatments and may require surgery.
OrthoATI is an autologous cell therapy that uses tendon-derived cells to repair and relieve chronic tendon injuries. The study compared the effectiveness of OrthoATI to surgery in treating lateral epicondylitis. The study met its primary endpoint, demonstrating that OrthoATI is as effective as surgery in treating this condition.
The final results of the study provide important evidence for the effectiveness of OrthoATI in treating severe, chronic, treatment-resistant lateral epicondylitis. This is significant as the condition can cause considerable pain and disability for those affected, and current treatment options may not be effective for all patients.
The data from the study confirms the effectiveness of OrthoATI in treating lateral epicondylitis and provides support for its use as an alternative treatment to surgery for this condition. This is important as conservative treatments are not always effective, and surgery carries risks and a longer recovery time.
Orthocell’s announcement of the final results from its clinical study comparing OrthoATI to surgery in treating severe, chronic, treatment-resistant lateral epicondylitis is significant for the millions of people affected by this condition. The study demonstrated that OrthoATI is as effective as surgery in treating lateral epicondylitis, providing an alternative treatment option for patients for whom conservative treatments have not been effective.
Overall, this final study from Orthocell confirms the effectiveness of OrthoATI in treating lateral epicondylitis and provides important evidence for its use as an alternative to surgery for this condition. This has the potential to benefit the millions of people affected by lateral epicondylitis who have not responded to conservative treatments and are considering surgery as a treatment option.
Keep Reading Latest the Tennis Update on Sportyjones.com!